Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Raw Materials (2023 - 2025)

Historic Raw Materials for Tg Therapeutics (TGTX) over the last 3 years, with Q3 2025 value amounting to $4.1 million.

  • Tg Therapeutics' Raw Materials rose 13408.3% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 13408.3%. This contributed to the annual value of $28.2 million for FY2024, which is 32769.67% up from last year.
  • Latest data reveals that Tg Therapeutics reported Raw Materials of $4.1 million as of Q3 2025, which was up 13408.3% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Raw Materials ranged from a high of $28.2 million in Q4 2024 and a low of $24000.0 during Q1 2023
  • Over the past 3 years, Tg Therapeutics' median Raw Materials value was $1.7 million (recorded in 2024), while the average stood at $4.9 million.
  • Over the last 5 years, Tg Therapeutics' Raw Materials had its largest YoY gain of 712916.67% in 2024, and its largest YoY loss of 4120.52% in 2024.
  • Tg Therapeutics' Raw Materials (Quarter) stood at $6.6 million in 2023, then skyrocketed by 327.7% to $28.2 million in 2024, then plummeted by 85.58% to $4.1 million in 2025.
  • Its Raw Materials stands at $4.1 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.1 million for Q1 2025.